Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer
Agilent Technologies, Inc. (A)
Last agilent technologies, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.agilent.com
Company Research
Source: Business Wire
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify cervical cancer patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use. Physicians in the United States can now gain valuable information to help them identify cervical cancer patients who are most likely to benefit from treatment with KEYTRUDA, an anti-PD1 immunotherapy manufactured by Merck (known as MSD outside the United States and Canada). PD-L1 IHC 22C3 pharmDx is now the first FDA-approved IHC test for determining PD-L1 expression in cervical cancer and is the first FDA-approved companion diagnostic to identify patients with cervical cancer for treatment with KEYTRUDA. This follows an initial FDA appr
Show less
Read more
Impact Snapshot
Event Time:
A
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
A alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
A alerts
High impacting Agilent Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
A
News
- Global Anatomic Pathology Market Booming: Set for US$ 92.8 Bn by 2034 as Cancer Diagnoses and Personalized Medicine Surge; says TNR, The Niche Research [Yahoo! Finance]Yahoo! Finance
- Declining Stock and Solid Fundamentals: Is The Market Wrong About Agilent Technologies, Inc. (NYSE:A)? [Yahoo! Finance]Yahoo! Finance
- Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products [Yahoo! Finance]Yahoo! Finance
- Single Nucleotide Polymorphism Genotyping Market Global Industry Analysis & Forecast 2018-2028: Pharmaceutical Development Accelerates SNP Genotyping Utilization [Yahoo! Finance]Yahoo! Finance
- Expansion of Organic and Sustainable Agriculture Catapults the Pesticide Detection Market; FMI Analysts Predict Market Valuation to Surpass US$ 3,049.50 million by 2034 [Yahoo! Finance]Yahoo! Finance
A
Earnings
- 2/27/24 - Beat
A
Sec Filings
- 4/10/24 - Form SC
- 3/27/24 - Form 4
- 3/25/24 - Form 144
- A's page on the SEC website